Iproteos and Oryzon: Spanish biotechs with the support of investors and progressing towards the market

, ,
Integral service around a transaction
BY : Diego GutiérrezNovember Wed, 2016
Good news for Spanish biotech, Iproteos has received a €1.5M round. Oryzon, which has been receiving venture capital backing since 2009, was able to go public last year and this week, after the good results published for its product, its share price has risen by 40%.
Iproteos receives a €1.5M round of funding

The Catalan  Iproteos,  which has several projects under development in the fields of schizophrenia, epilepsy and atherosclerosis, has closed a €1.5M round of funding led by Caixa Capital Risc and in which Kinled Holding - an investment company based in Hong Kong with offices in London, New York and Zurich - and the biotech company ASCIL Biopharm have also participated.

This round allows Ipotreos, which has several products in the pre-clinical stage, to move towards the market with both financial resources and the experience of knowledgeable agents in the sector.

Iproteos also has its own technology, IPROTech, a cutting-edge platform that combines computer and biotechnological tools developed by Iproteos' own research team for the design of innovative therapeutic molecules, called peptidomimetics.

Previously, Iproteos had raised €100,000 through a crowdfunding campaign.

Oryzon soars more than 40% in stock market on advances in its anti-tumour drug in development, which has a deal with Roche


The share price of Oryzon (40%) on Wednesday 15 November as it obtained positive results in the first clinical trials of its most advanced anti-tumour drug, ORY-1001, in patients.

In the Thursday and Friday sessions investors took the opportunity to cash in and the stock corrected by 2%, but on Monday it rose again.

Among the investors that have made a profit is the Generalitat, through the company for the promotion and industrial location of Catalonia Avançsa. The Generalitat sold shares at €4.63 for a total amount of €449,762, which generated a profit of €212,264.

The listed company has an agreement, the most important in Spanish biotechnology, with Roche, under which the Catalan lab will receive up to €500M from the Swiss multinational as clinical research and market launch of the drug progresses. With this milestone, Oryzon has completed its part of the molecule's development.

Oryzon, founded in 2001, went public in December 2015, having received two rounds of investment worth €28M.

If you are seeking funding, get in touch with us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.


Other posts that may interest you

Wallapop, Letgo and HallStreet: M&A Spanish companies to gain strength in international market

Diversion of venture capital in Spanish companies: Tyba and Otogami


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?